On Monday, the FDA approved a new drug for Alzheimer’s disease—the first in nearly two decades. Biogen’s aducanumab aims to slow the cognitive decline often associated with the disease.
Other researchers are not convinced that these biomarkers vary by race, primarily because so little Alzheimer’s research has been conducted on Black and Latinx people.
For someone to be diagnosed with dementia, they have to have significant decline in more than one cognitive area,” says Neuropsychologist Elise Caccappolo, Ph.D., of CUIMC
It is well established that people who had fewer opportunities to receive education when they were children are at higher risk for Alzheimer’s disease later in life, noted Dr. Jennifer Manly
